Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence and correlates of pharmacotherapy metabolized by CYP2C19, CYP2C9, CYP2D6, and UGT1A1 in the population sample.

Personalized medicine - 1 Apr 2026

Anfinogenova Nina D, Stepanov Vadim A, Kuznetsova Alina D, Chesalov Nazary P, Popov Sergey V, Repin Alexey N

Abstract excerpt

OBJECTIVE: Telecommunication-based cross-sectional study aimed to assess prevalence and health-related correlates of pharmacogenetic (PGx) drug administration. METHODS: Online survey population sample (n = 2149) was initiated by SMS invitations to random adults. Questionnaire included questions on demographics, health, and clinical pharmacology. PGx drugs were identified using ClinPGx/PharmGKB database. Combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Sectional Studies
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP2D6

Share to Drug-Related Side Effects and Adverse Reactions

Share to Glucuronosyltransferase

Share to Pharmacogenetics

Share to Surveys and Questionnaires

Source

Identifiers

PMID: 42011547
DOI: 10.1080/17410541.2026.2659007

Genes

CYP2C19
UGT1A1
CYP2C9
SMS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence and correlates of pharmacotherapy metabolized by CYP2C19, CYP2C9, CYP2D6, and UGT1A1 in the population sample.PMID 42011547Read ↗

Pharmacotherapy Associated with CYP2C19, CYP2C9, CYP2D6, and UGT1A1 Genes in Population Sample: Observational Cross Sectional Analytical StudySemantic proximity Read ↗

Use of Pharmacogenetic Drugs by the Dutch PopulationSemantic proximity Read ↗

Self-reported pharmacogenetic medication use in the <i>Our Future Health</i> cohortSemantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

Genetic Risk Factors for Adverse Drug ReactionsSemantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

Pharmacokinetic recall study of Estonian Biobank participants carrying novel genetic variants in CYP2C19 and CYP2D6Semantic proximity Read ↗

Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications.Semantic proximity Read ↗

CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health SystemSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Study on genetic polymorphisms and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in Han Chinese populationSemantic proximity Read ↗

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.